{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:09:15Z","timestamp":1790017755745,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,2]]},"DOI":"10.7759\/cureus.78396","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:32:31Z","timestamp":1738560751000},"source":"Crossref","is-referenced-by-count":1,"title":["Oral Cornstarch and Glycyrrhizin Improve Severe Liver Injury Caused by Glycogen Storage Disease Type IXa"],"prefix":"10.7759","author":[{"given":"Masanori","family":"Miyaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kuranobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0364-2","article-title":"Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Kishnani PS","year":"2019","unstructured":"Kishnani PS, Goldstein J, Austin SL, et al.. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019, 21:772-89. 10.1038\/s41436-018-0364-2","journal-title":"Genet Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.06.007","article-title":"Glycogen storage disease type IX: high variability in clinical phenotype","volume":"92","author":"Beauchamp NJ","year":"2007","unstructured":"Beauchamp NJ, Dalton A, Ramaswami U, et al.. Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab. 2007, 92:88-99. 10.1016\/j.ymgme.2007.06.007","journal-title":"Mol Genet Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.05.010","article-title":"Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies","volume":"104","author":"Davit-Spraul A","year":"2011","unstructured":"Davit-Spraul A, Piraud M, Dobbelaere D, et al.. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011, 104:137-43. 10.1016\/j.ymgme.2011.05.010","journal-title":"Mol Genet Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.10.004","article-title":"Benign or not benign? Deep phenotyping of liver glycogen storage disease IX","volume":"131","author":"Fernandes SA","year":"2020","unstructured":"Fernandes SA, Cooper GE, Gibson RA, Kishnani PS. Benign or not benign? Deep phenotyping of liver glycogen storage disease IX. Mol Genet Metab. 2020, 131:299-305. 10.1016\/j.ymgme.2020.10.004","journal-title":"Mol Genet Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/srep44408","article-title":"Hepatic mitochondrial dysfunction is a feature of glycogen storage disease type Ia (GSDIa)","volume":"7","author":"Farah BL","year":"2017","unstructured":"Farah BL, Sinha RA, Wu Y, et al.. Hepatic mitochondrial dysfunction is a feature of glycogen storage disease type Ia (GSDIa). Sci Rep. 2017, 7:44408. 10.1038\/srep44408","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.04.017","article-title":"Liver histology in children with glycogen storage disorders type VI and IX","volume":"53","author":"Degrassi I","year":"2021","unstructured":"Degrassi I, Deheragoda M, Creegen D, Mundy H, Mustafa A, Vara R, Hadzic N. Liver histology in children with glycogen storage disorders type VI and IX. Dig Liver Dis. 2021, 53:86-93. 10.1016\/j.dld.2020.04.017","journal-title":"Dig Liver Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20051","article-title":"Apoptosis: the nexus of liver injury and fibrosis","volume":"39","author":"Canbay A","year":"2004","unstructured":"Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004, 39:273-8. 10.1002\/hep.20051","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.03.009","article-title":"Aggressive therapy improves cirrhosis in glycogen storage disease type IX","volume":"109","author":"Tsilianidis LA","year":"2013","unstructured":"Tsilianidis LA, Fiske LM, Siegel S, Lumpkin C, Hoyt K, Wasserstein M, Weinstein DA. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013, 109:179-82. 10.1016\/j.ymgme.2013.03.009","journal-title":"Mol Genet Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0479-0","article-title":"A novel starch for the treatment of glycogen storage diseases","volume":"30","author":"Bhattacharya K","year":"2007","unstructured":"Bhattacharya K, Orton RC, Qi X, et al.. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis. 2007, 30:350-7. 10.1007\/s10545-007-0479-0","journal-title":"J Inherit Metab Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmz092","article-title":"Dietary management of the glycogen storage diseases: evolution of treatment and ongoing controversies","volume":"11","author":"Ross KM","year":"2020","unstructured":"Ross KM, Ferrecchia IA, Dahlberg KR, Dambska M, Ryan PT, Weinstein DA. Dietary management of the glycogen storage diseases: evolution of treatment and ongoing controversies. Adv Nutr. 2020, 11:439-46. 10.1093\/advances\/nmz092","journal-title":"Adv Nutr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.025","article-title":"Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25","volume":"110","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Li L, Qi C, Hua S, Fei X, Gong F, Fang M. Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25. Biomed Pharmacother. 2019, 110:692-9. 10.1016\/j.biopha.2018.12.025","journal-title":"Biomed Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202006_21706","article-title":"Glycyrrhizin improves inflammation and apoptosis via suppressing HMGB1 and PI3K\/mTOR pathway in lipopolysaccharide-induced acute liver injury","volume":"24","author":"Shen CH","year":"2020","unstructured":"Shen CH, Ma ZY, Li JH, Li RD, Tao YF, Zhang QB, Wang ZX. Glycyrrhizin improves inflammation and apoptosis via suppressing HMGB1 and PI3K\/mTOR pathway in lipopolysaccharide-induced acute liver injury. Eur Rev Med Pharmacol Sci. 2020, 24:7122-30. 10.26355\/eurrev_202006_21706","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2022.124416","article-title":"Interleukin 25 and its biological features and function in intestinal diseases","volume":"47","author":"Jiang W","year":"2022","unstructured":"Jiang W, Wang Z, Zhang J, Li M. Interleukin 25 and its biological features and function in intestinal diseases. Cent Eur J Immunol. 2022, 47:362-72. 10.5114\/ceji.2022.124416","journal-title":"Cent Eur J Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220977823","article-title":"Post-treatment with glycyrrhizin can attenuate hepatic mitochondrial damage induced by acetaminophen in mice","volume":"246","author":"Dang XL","year":"2021","unstructured":"Dang XL, Yang LF, Shi L, et al.. Post-treatment with glycyrrhizin can attenuate hepatic mitochondrial damage induced by acetaminophen in mice. Exp Biol Med (Maywood). 2021, 246:1219-27. 10.1177\/1535370220977823","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.069419","article-title":"Glycyrrhizin protects against acetaminophen-induced acute liver injury via alleviating tumor necrosis factor \u03b1-mediated apoptosis","volume":"44","author":"Yan T","year":"2016","unstructured":"Yan T, Wang H, Zhao M, et al.. Glycyrrhizin protects against acetaminophen-induced acute liver injury via alleviating tumor necrosis factor \u03b1-mediated apoptosis. Drug Metab Dispos. 2016, 44:720-31. 10.1124\/dmd.116.069419","journal-title":"Drug Metab Dispos"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329920-oral-cornstarch-and-glycyrrhizin-improve-severe-liver-injury-caused-by-glycogen-storage-disease-type-ixa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:32:34Z","timestamp":1738560754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329920-oral-cornstarch-and-glycyrrhizin-improve-severe-liver-injury-caused-by-glycogen-storage-disease-type-ixa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,2]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.78396","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,2]]}}}